SCHEDULE 13G/A: Lance Friedman Amends Stake in Aspire Biopharma Holdings, Inc., Reporting 4.52% Ownership

Lance Friedman has filed an Amendment No. 9 to Schedule 13G, disclosing a 4.52% beneficial ownership stake in Aspire Biopharma Holdings, Inc. as of May 6, 2025.

Summary

• Lance Friedman filed an Amendment No. 9 to Schedule 13G with the SEC.
• The filing reports beneficial ownership in Aspire Biopharma Holdings, Inc. (CUSIP No. 738920107).
• Mr. Friedman beneficially owns an aggregate of 2,207,886 shares of common stock.
• This ownership represents 4.52% of the class of securities.
• The shares include 2,200,886 shares held by Blackstone Capital Advisors, Inc. and 7,000 shares held by Thor Special Situations LLC.
• Mr. Friedman holds sole voting power and sole dispositive power over all 2,207,886 shares.

Sentiment

Score: 5

Explanation: The document is a routine Schedule 13G amendment disclosing beneficial ownership, which is a factual filing and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• The continued beneficial ownership by Lance Friedman, a significant individual investor, may signal ongoing investor confidence in Aspire Biopharma Holdings, Inc.

Future Outlook

NA

Management Comments

• Lance Friedman certified that, to the best of his knowledge and belief, the securities referred to were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This Schedule 13G filing is a routine disclosure of beneficial ownership and does not provide specific industry context or trends for the biopharma sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant individual investor's stake, confirming a passive investment position.

Key Dates

Keywords

Aspire Biopharma Holdings Inc., Lance Friedman, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional investor, biopharma